11 min listen
AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
10 minutes
Released:
Jan 24, 2023
Format:
Podcast episode
Description
Although lipoprotein(a) is believed to play a causal role in atherogenesis, there are no approved therapies to help lower it. The OCEAN(a) DOSE study examined a drug specifically designed to lower lipoprotein(a) through RNA interference. In this interview, Michelle L. O'Donoghue MD, MPH and Nanette Kass Wenger MD, MACC discuss AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Released:
Jan 24, 2023
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: STRENGTH Trial: High-Dose Omega-3 Fatty Acids vs. Corn Oil: The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research